NovoCure Limited (NVCR) Stock Price & How to Invest
Last updated July 2026
Short answer
NVCR is NovoCure, a commercial-stage oncology device maker whose Tumor Treating Fields (TTFields) wearables (Optune Gio, Lua, and Pax) generate real product revenue (~$655M in 2025), so investing in it is a bet on expanding TTFields into new cancers while the company still runs GAAP losses.
NVCR stock price
As of 2026-07-23, NovoCure Limited (NVCR) last closed at $19.99, up 59.4% over the past year. Over the past 52 weeks it has traded between $10.03 and $19.99.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or NovoCure Limited's investor relations page. Walnut is informational, not investment advice.
What does NovoCure Limited (NVCR) do?
NovoCure Ltd. (Nasdaq: NVCR) is an oncology medical device company built around Tumor Treating Fields (TTFields), a therapy that delivers low-intensity alternating electric fields through wearable arrays to disrupt cancer cell division. Its FDA-approved Optune platform spans Optune Gio for glioblastoma, Optune Lua for metastatic non-small cell lung cancer and malignant pleural mesothelioma, and Optune Pax, approved in February 2026 for locally advanced pancreatic cancer. The company reported full-year 2025 net revenue of about $655 million (up ~8%) with roughly 4,620 active patients on therapy at year-end.
The investment picture is a growth-versus-profitability tension. The core glioblastoma business is mature and slower-growing, so the equity story now hinges on newer indications (lung and pancreatic) and international expansion driving the next leg. Management guided 2026 revenue to $690 million to $710 million, but the company still posts GAAP net losses (a $71.1 million loss in Q1 2026, inflated by a one-time share-based-comp charge tied to the Optune Pax approval). Gross margins near 78% and a cash position over $400 million give runway, but the path to sustained profitability depends heavily on adoption of the new launches and clinical readouts in additional tumor types.
What's driving NovoCure Limited (NVCR)?
1. New-indication launches (Optune Pax and Lua)
The February 2026 U.S. approval of Optune Pax for locally advanced pancreatic cancer opens a large new addressable market, and early launch metrics were encouraging (hundreds of certified providers and prescriptions within the first weeks). Optune Lua in lung cancer and mesothelioma is also ramping, with revenue roughly doubling year over year off a small base. These launches are the primary growth engine now that glioblastoma is mature.
2. International expansion and reimbursement wins
Ex-U.S. markets and favorable currency drove much of the recent revenue growth, and NovoCure continues to secure national reimbursement coverage in markets such as Spain. Broadening payer coverage across Europe and other regions can lift active-patient counts without requiring new clinical approvals.
3. Margin and cost discipline
Gross margin improved to about 78% in Q1 2026 from 75% a year earlier, helped by lower array costs and better supplier pricing. Continued margin gains, if paired with revenue growth, are the mechanism by which the company could narrow its losses over time.
4. Clinical pipeline in additional tumor types
TTFields is being studied across multiple cancers, and positive readouts (like the PANOVA-3 pancreatic trial that supported Optune Pax) can each unlock a new indication. The pipeline extends the potential runway well beyond the current approved uses if trials succeed.
What are the risks to NovoCure Limited (NVCR)?
NovoCure remains GAAP unprofitable and depends on new launches converting into durable revenue, which is not guaranteed. Its Phase 3 TRIDENT trial in newly diagnosed glioblastoma failed to meet its primary overall-survival endpoint, a reminder that clinical bets can disappoint and that the mature glioblastoma base offers limited upside. Reimbursement decisions, physician adoption of an unfamiliar device modality, and competition from drug-based oncology standards of care all create uncertainty. The stock has been volatile, and heavy reliance on a single technology platform concentrates risk. Currency swings that recently helped revenue can also reverse.
How is NovoCure Limited (NVCR) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see NovoCure Limited's investor relations page or your broker.
- Revenue (FY2025): ~$655M
- Revenue (Q1 2026): ~$174M (up ~12% YoY)
- 2026 revenue guidance: ~$690M to $710M
- Gross margin (Q1 2026): ~78%
- Net loss (Q1 2026): ~$71M (~$0.62/share)
- Cash & short-term investments: ~$432M (Mar 31, 2026)
- Market cap: ~$1.9B to $2.0B
NovoCure trades as a mid-single-digit-growth medical device company that is still not GAAP profitable, so it is valued more on revenue and future-indication optionality than on earnings. The recent quarterly loss was amplified by a roughly $43 million one-time share-based-comp charge linked to the Optune Pax approval. Over $400 million in cash against modest debt gives operating runway while the newer launches scale.
Who competes with NovoCure Limited (NVCR)?
Oncology drug standards of care
NovoCure's biggest competition is not another electric-fields device but the systemic therapies (chemotherapy, immunotherapy, and targeted drugs) from large pharma such as Merck, Bristol Myers Squibb, and Roche that define first-line treatment in lung, pancreatic, and brain cancers. TTFields must prove added benefit on top of, or versus, these regimens.
Medical device and diversified med-tech
As a device maker, NovoCure sits in the broader oncology and med-tech universe alongside diversified players like Boston Scientific, Medtronic, and interventional-oncology firms. None deliver TTFields, but they compete for hospital budgets, physician attention, and med-tech investor capital.
Emerging electric-field and novel-modality research
TTFields is largely proprietary today, but academic and preclinical work on alternating-electric-field and other novel physical cancer modalities represents potential future competition. For now NovoCure holds a dominant commercial position in this specific therapy category.
How to invest in NovoCure Limited (NVCR)
There are three common ways to get NVCR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so NVCR sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where NVCR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on NovoCure Limited (NVCR)
NovoCure is a revenue-generating, still-unprofitable oncology device play where the thesis rides on new-indication launches offsetting a mature glioblastoma base.
More on NovoCure Limited (NVCR)
Whether NVCR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NVCR a buy?, and where the stock could go from here in the NVCR stock forecast.
For income investors, whether NVCR pays a dividend and how the payout looks is covered in does NVCR pay a dividend?
Build a basket around NVCR with Walnut
Use NovoCure Limited as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does NovoCure (NVCR) do?
+
NovoCure is an oncology medical device company that makes Tumor Treating Fields (TTFields) therapy, delivered through wearable Optune devices that use low-intensity alternating electric fields to disrupt cancer cell division. Its approved products treat glioblastoma, lung cancer, mesothelioma, and pancreatic cancer.
Is NVCR profitable?
+
No. NovoCure generates substantial product revenue (about $655 million in 2025) but remains unprofitable on a GAAP basis, reporting a net loss of roughly $71 million in Q1 2026. That quarter's loss was widened by a one-time share-based-compensation charge tied to a product approval.
What are NovoCure's main products?
+
The Optune platform includes Optune Gio for glioblastoma, Optune Lua for metastatic non-small cell lung cancer and malignant pleural mesothelioma, and Optune Pax, approved in February 2026 for locally advanced pancreatic cancer. All deliver the same TTFields technology to different tumor types.
Why is NovoCure's growth accelerating in some areas but not others?
+
The core glioblastoma business is mature and grows slowly, so recent growth is driven by newer launches in lung and pancreatic cancer plus international expansion and reimbursement wins. The Optune Pax pancreatic launch and Optune Lua lung ramp are the key growth engines.
What happened with the TRIDENT trial?
+
NovoCure's Phase 3 TRIDENT trial in newly diagnosed glioblastoma failed to meet its primary overall-survival endpoint, meaning starting TTFields during chemoradiation showed no statistically significant benefit over the current approach. The full dataset is slated for presentation at ASTRO 2026.
How large is NovoCure?
+
NovoCure is a mid-cap company with a market capitalization around $1.9 billion to $2.0 billion as of mid-2026, with the stock trading in the high teens and a 52-week range roughly between $10 and $19. It carries over $400 million in cash and short-term investments.
Who competes with NovoCure?
+
TTFields is largely proprietary, so NovoCure's real competition is the systemic drug standards of care (chemotherapy, immunotherapy, targeted drugs) from large pharma companies, plus broader med-tech firms competing for hospital budgets. Emerging electric-field research is a longer-term potential rival.
What are the biggest risks for NVCR investors?
+
Key risks include ongoing GAAP losses, dependence on new-indication launches converting into durable revenue, clinical-trial disappointments (like TRIDENT), reimbursement and adoption hurdles for an unfamiliar device, competition from drug therapies, and concentration in a single technology platform. The stock has also been volatile.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with NovoCure Limited's investor relations page or your broker before making investment decisions.